ImmunityBio Faces Class Action Lawsuit Over Alleged Misstatements About Anktiva

ImmunityBio, Inc. (NASDAQ: IBRX) is facing a class action lawsuit alleging false and misleading statements about its product Anktiva. The lawsuit claims that the company and its executives overstated the drug's capabilities, leading to investor losses. The deadline for investors to seek lead plaintiff status in the lawsuit is May 26, 2026.

By Robbins Geller Rudman & Dowd LLP · PR Newswire · April 16, 2026, 13:05 UTC

Tickers: $IBRX

Topics: biotechnology class action lawsuit FDA warning misbranding securities fraud

Read the full article at PR Newswire

More World news

Al Mouj Muscat Receives Three Architectural Awards at International and Arabian Property Awards 2026 PR Newswire · November 12, 2026, 17:01 UTC
SoftBank Reports $7.1 Billion Quarterly Loss Driven by Natural Gas Turbine Over-Ordering TechCrunch · November 12, 2026, 17:00 UTC
PayPal and Kiva Renew Long-Term Partnership to Support Global Microloans PR Newswire · November 12, 2026, 17:00 UTC
Tesla to Discontinue Cybertruck Production by Summer 2027 to Prioritize Cybercab The Verge · November 12, 2026, 17:00 UTC
Absci Reports Q3 2026 Financial Results and Clinical Updates for ABS-201 Motley Fool · November 12, 2026, 16:54 UTC
Acurx Pharmaceuticals Reports Q3 2026 Financial Results and Initiates PATHFINDER Trial Enrollment Motley Fool · November 12, 2026, 16:54 UTC
Fermi Inc. Reports Q3 2026 Net Loss of $141.6 Million Amid Infrastructure Expansion Motley Fool · November 12, 2026, 16:54 UTC
Google Wallet Introduces Digital Home Key Support via Aliro Standard The Verge · November 12, 2026, 16:56 UTC
Analyst Ming-Chi Kuo Suggests Nvidia CEO Resignation May Have Limited Near-Term Stock Impact Seeking Alpha · November 12, 2026, 16:53 UTC
Solo Brands Lowers Net Sales Outlook While Projecting 2026 Adjusted EBITDA Growth Seeking Alpha · November 12, 2026, 16:50 UTC